Last updated: February 27, 2026
What is JINTELI?
JINTELI (rimegepant) is an oral calcitonin gene-related peptide (CGRP) receptor antagonist, approved by the FDA for the acute treatment of migraines with or without aura in adult patients. It is marketed by Pfizer under the brand name Nurtec ODT in the United States.
What Are Key Components of JINTELI Formulation?
JINTELI's formulation includes:
- Active Pharmaceutical Ingredient (API): Rimegepant
- Excipients:
- Mannitol (filler/biller)
- Crospovidone (disintegrant)
- Microcrystalline cellulose (filler)
- Magnesium stearate (lubricant)
- Aspartame (sweetener)
- Flavoring agents
- Other stabilizers and pH adjusters
The formulation is designed for rapid disintegration and absorption in the oral cavity.
How Do Excipient Strategies Influence JINTELI’s Formulation?
Excipient choices directly affect:
- Bioavailability: Disintegrants like crospovidone ensure quick tablet breakdown, facilitating rapid API release.
- Stability: Fillers like mannitol contribute to physical stability and mask taste.
- Manufacturability: Microcrystalline cellulose improves flow properties during production.
- Patient Compliance: Sweeteners and flavoring enhance palatability, crucial for oral disintegrating tablets (ODTs).
Selecting excipients with high compatibility and regulatory acceptance reduces development risks and accelerates market entry.
What Are the Commercial Opportunities Centered on Excipient Strategies?
1. Development of Alternative Formulations
- Different dosage forms: Orally disintegrating films, melts, or suspensions.
- Target markets: Pediatrics or populations with swallowing difficulties.
- Potential excipients: Gellan gum, polaxamers, or melted matrices for fast absorption.
2. Excipient Innovation
- Functional excipients: Incorporate bioadhesives or permeation enhancers.
- Dual-purpose excipients: Combine disintegrants and taste-masking agents.
- Natural excipients: Respond to demand for "clean-label" formulations.
3. Supply Chain and Contract Manufacturing
- Excipient manufacturing partnerships: Expand production capacity, especially for high-demand excipients like mannitol or crospovidone.
- Licensing: Offer proprietary excipient variants optimized for CGRP antagonists or similar APIs.
4. Regulatory and Compliance Opportunities
- Tailored excipient profiles: Meet evolving regulatory standards, including reduced allergenicity and gluten-free variants.
- Patent landscapes: Protect innovative excipient combinations to extend product lifecycle.
5. Cost Optimization
- Bulk procurement: Reduce unit costs for key excipients.
- Process innovations: Minimize excipient excipient-related waste or variability.
How Do Composition and Excipient Selection Impact JINTELI’s Market Position?
The effectiveness of JINTELI’s formulation correlates with excipient quality and strategy. Expanding formulations into new delivery systems (e.g., ODTs, films) with optimized excipients can open access to additional patient segments. Strategic partnerships in excipient manufacturing can reduce costs and improve supply reliability, supporting global expansion.
Existing Market Data and Trends
- Global migraine treatment market: Valued at USD 4.2 billion in 2021, projected CAGR of 4.5% (Grand View Research).
- Oral disintegrating tablets (ODTs): Segment growing at 6% annually, driven by aging populations and patient preferences.
- Excipient innovation market: Estimated USD 3.5 billion in 2022, with a focus on natural and functional excipients.
Regulatory Context
The US FDA, EMA, and other bodies require detailed excipient profiles, particularly for new formulations. The development of excipients with established safety profiles can expedite approvals.
Key Takeaways
- Excipient selection in JINTELI’s formulation maximizes bioavailability, stability, and patient compliance.
- Opportunities include new oral dosage forms, excipient innovation, and supply chain optimization.
- Strategic partnerships with excipient suppliers support cost reduction and global market access.
- Regulatory acceptance of excipient profiles influences time-to-market and patent protection.
- Growing demand for advanced or natural excipients presents innovation pathways for future formulations.
FAQs
1. What excipients are critical in JINTELI’s current formulation?
Mannitol, crospovidone, microcrystalline cellulose, magnesium stearate, and aspartame.
2. Can excipient choices influence JINTELI’s market expansion?
Yes. Developing alternative formulations with innovative excipients can address unmet patient needs, expanding the market.
3. What is the role of natural excipients in future JINTELI formulations?
They meet consumer demand for clean-label products and may reduce regulatory hurdles related to safety.
4. How does supply chain management impact excipient availability for JINTELI?
Strong partnerships and bulk procurement can ensure supply stability, reducing production delays.
5. Are there patent opportunities related to excipient strategies for JINTELI?
Yes. Novel excipient combinations or delivery systems can be patented, extending product lifecycle.
References
[1] Grand View Research. (2022). Migraine treatment market size, share & trends analysis.
[2] U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Drug Products.
[3] European Medicines Agency. (2022). Guideline on excipients in the label and package leaflet.
